Each tablet contains Cilnidipine 10mg + Olmesartan 20/40mg
For the treatment of essential hypertension
Cilnidipine is a dihydropyridine calcium-channel blocker. It inhibits cellular influx of calcium, thus causing vasodilatation. It has greater selectivity forvascular smooth muscle. Olmesartan- Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle.
One tablet,once daily in the morning.
Nulong OL is contraindicated in patients with aortic stenosis and in patients with known hypersensitivity to any active ingredients or any other component of this product.
Cilnidipine- Hypotension, poor cardiac reserve, heart failure, chronic renal insufficiency and hepatic dysfunction. Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain following administration. Olmesartan- Observe for signs and symptoms of hypotension in volume- or salt-depleted patients with treatment initiation, Monitor for worsening renal function in patients with renal impairment.
Not recommended for use in pregnancy.It is not known whether olmesartan is excreted in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Not recommended to be used in pediatric patients.
Cilnidipine can interact with aldesleukin, quinidine, phenytoin, rifampicin, erythromycin, other anti-hypertensive drugs and anti-psychotic drugs. Olmesartan used concomitantly with NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect.
Headache, dizziness, peripheral edema, flushing rash, gingival hyperplasia, palpitations and GI disturbances.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS